Skip to content
HowShorted

Avidity Biosciences, Inc. short interest in 2023

In 2023, Avidity Biosciences, Inc.'s disclosed short interest ran from 14.45% of shares outstanding on 13 Jan 2023 to 13.26% on 29 Dec 2023, a change of -1.19 percentage points. The year's high was 22.66% on 14 Jul 2023 and its low 11.13% on 15 Feb 2023, averaging 16.98% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.55 days on 14 Jul 2023. Full history: Avidity Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Avidity Biosciences, Inc. in 2023

2023 in figures

Start of year
14.45% (13 Jan 2023)
End of year
13.26% (29 Dec 2023)
Change
-1.19 pp
High
22.66% (14 Jul 2023)
Low
11.13% (15 Feb 2023)
Average
16.98%
Highest days to cover
32.55 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Avidity Biosciences, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202314.45%8.58
31 Jan 202313.76%10.78
15 Feb 202311.13%11.27
28 Feb 202311.73%9.9310-K filed, results (8-K)
15 Mar 202312.27%9.08
31 Mar 202315.41%6.52
14 Apr 202316.01%8.02
28 Apr 202314.02%6.32
15 May 202318.12%8.5410-Q filed, results (8-K)
31 May 202318.93%14.55
15 Jun 202319.91%11.43
30 Jun 202322.19%8.99
14 Jul 202322.66%32.55
31 Jul 202321.09%23.93
15 Aug 202321.68%24.6010-Q filed, results (8-K)
31 Aug 202322.10%28.07
15 Sep 202322.56%12.57
29 Sep 202320.90%20.31
13 Oct 202315.61%14.02
31 Oct 202315.66%17.89
15 Nov 202314.66%16.4610-Q filed, results (8-K)
30 Nov 202314.88%3.40
15 Dec 202314.41%7.52
29 Dec 202313.26%10.19

See also: Avidity Biosciences, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.